Michael Handler
Concepts (483)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Brain Neoplasms | 28 | 2023 | 979 | 2.770 |
Why?
| Ependymoma | 15 | 2020 | 158 | 1.810 |
Why?
| Hydrocephalus | 5 | 2022 | 81 | 1.650 |
Why?
| Neural Tube Defects | 3 | 2021 | 62 | 1.390 |
Why?
| Brain Stem Neoplasms | 8 | 2018 | 86 | 1.390 |
Why?
| Neurosurgical Procedures | 7 | 2023 | 157 | 1.360 |
Why?
| Decompression, Surgical | 4 | 2022 | 93 | 1.260 |
Why?
| Neurosurgery | 2 | 2023 | 26 | 1.260 |
Why?
| Magnetic Resonance Imaging | 18 | 2023 | 3087 | 1.240 |
Why?
| Arnold-Chiari Malformation | 4 | 2022 | 30 | 1.170 |
Why?
| Glioma | 7 | 2021 | 296 | 1.150 |
Why?
| Craniopharyngioma | 8 | 2020 | 65 | 1.050 |
Why?
| Cerebrospinal Fluid Shunts | 5 | 2017 | 28 | 1.010 |
Why?
| Spinal Injuries | 2 | 2019 | 48 | 1.000 |
Why?
| Germinoma | 2 | 2022 | 12 | 0.900 |
Why?
| Child | 65 | 2023 | 18555 | 0.870 |
Why?
| Pineal Gland | 1 | 2022 | 12 | 0.840 |
Why?
| Pinealoma | 1 | 2022 | 11 | 0.840 |
Why?
| Child, Preschool | 45 | 2019 | 9175 | 0.730 |
Why?
| Epilepsy | 5 | 2017 | 290 | 0.680 |
Why?
| Pituitary Neoplasms | 5 | 2020 | 157 | 0.640 |
Why?
| Meningomyelocele | 4 | 2022 | 57 | 0.630 |
Why?
| Tomography, X-Ray Computed | 9 | 2020 | 2409 | 0.620 |
Why?
| Skull Neoplasms | 1 | 2017 | 21 | 0.610 |
Why?
| Medulloblastoma | 6 | 2022 | 172 | 0.600 |
Why?
| Cerebellar Neoplasms | 5 | 2022 | 131 | 0.590 |
Why?
| Infant | 35 | 2019 | 8002 | 0.580 |
Why?
| Sarcoma, Ewing | 1 | 2017 | 62 | 0.570 |
Why?
| Humans | 105 | 2023 | 115908 | 0.560 |
Why?
| Gene Expression Regulation, Neoplastic | 13 | 2022 | 1143 | 0.530 |
Why?
| Colectomy | 1 | 2016 | 87 | 0.510 |
Why?
| Ventriculoperitoneal Shunt | 3 | 2019 | 30 | 0.500 |
Why?
| Infratentorial Neoplasms | 4 | 2019 | 45 | 0.500 |
Why?
| Ganglioglioma | 4 | 2016 | 31 | 0.500 |
Why?
| Rhabdoid Tumor | 3 | 2013 | 80 | 0.500 |
Why?
| Female | 59 | 2022 | 60086 | 0.490 |
Why?
| Child Abuse | 4 | 2015 | 455 | 0.490 |
Why?
| Gene Expression Profiling | 15 | 2020 | 1548 | 0.490 |
Why?
| Male | 55 | 2022 | 56128 | 0.490 |
Why?
| Wounds, Nonpenetrating | 2 | 2019 | 228 | 0.480 |
Why?
| Reoperation | 2 | 2016 | 526 | 0.480 |
Why?
| Adolescent | 38 | 2021 | 17955 | 0.470 |
Why?
| Biomarkers, Tumor | 8 | 2018 | 1045 | 0.470 |
Why?
| Craniotomy | 2 | 2012 | 67 | 0.470 |
Why?
| Astrocytoma | 6 | 2013 | 108 | 0.470 |
Why?
| Retrospective Studies | 27 | 2022 | 12616 | 0.470 |
Why?
| Pleural Cavity | 1 | 2013 | 2 | 0.460 |
Why?
| Cerebral Cortex | 1 | 2017 | 390 | 0.460 |
Why?
| Neoplasm Recurrence, Local | 5 | 2014 | 862 | 0.450 |
Why?
| Supratentorial Neoplasms | 3 | 2019 | 17 | 0.450 |
Why?
| Colitis | 1 | 2016 | 226 | 0.440 |
Why?
| Crohn Disease | 1 | 2016 | 197 | 0.420 |
Why?
| Image Processing, Computer-Assisted | 2 | 2020 | 694 | 0.420 |
Why?
| Pons | 4 | 2015 | 30 | 0.420 |
Why?
| Teratoma | 2 | 2011 | 92 | 0.400 |
Why?
| Accidents | 1 | 2012 | 41 | 0.400 |
Why?
| Brain Injuries | 2 | 2015 | 451 | 0.370 |
Why?
| Infant, Newborn | 18 | 2019 | 5089 | 0.370 |
Why?
| Treatment Outcome | 18 | 2022 | 9166 | 0.370 |
Why?
| Cervical Vertebrae | 2 | 2015 | 104 | 0.360 |
Why?
| Head Injuries, Closed | 1 | 2010 | 48 | 0.350 |
Why?
| Central Nervous System | 2 | 2014 | 239 | 0.350 |
Why?
| Membrane Proteins | 3 | 2012 | 1033 | 0.340 |
Why?
| Prognosis | 16 | 2019 | 3342 | 0.330 |
Why?
| Proto-Oncogene Proteins B-raf | 3 | 2017 | 190 | 0.330 |
Why?
| Postoperative Complications | 6 | 2022 | 2167 | 0.320 |
Why?
| Chromosomes, Human, Pair 1 | 2 | 2019 | 69 | 0.310 |
Why?
| Syringomyelia | 2 | 2011 | 11 | 0.310 |
Why?
| Cerebrospinal Fluid | 2 | 2007 | 88 | 0.310 |
Why?
| Oligonucleotide Array Sequence Analysis | 12 | 2016 | 754 | 0.310 |
Why?
| Antineoplastic Combined Chemotherapy Protocols | 7 | 2019 | 1360 | 0.300 |
Why?
| Intracranial Hemorrhages | 2 | 2015 | 76 | 0.300 |
Why?
| Spinal Cord Neoplasms | 3 | 2009 | 40 | 0.300 |
Why?
| Transcriptome | 5 | 2022 | 742 | 0.280 |
Why?
| RNA, Messenger | 9 | 2017 | 2581 | 0.280 |
Why?
| Cell Line, Tumor | 11 | 2018 | 2749 | 0.280 |
Why?
| Vancomycin | 1 | 2007 | 76 | 0.260 |
Why?
| Onchocerciasis | 2 | 2015 | 7 | 0.260 |
Why?
| Chloroquine | 2 | 2017 | 52 | 0.260 |
Why?
| Proto-Oncogene Proteins | 3 | 2016 | 609 | 0.250 |
Why?
| Cerebral Hemorrhage | 2 | 2017 | 97 | 0.250 |
Why?
| Immunophenotyping | 2 | 2017 | 273 | 0.250 |
Why?
| Glioblastoma | 4 | 2013 | 251 | 0.240 |
Why?
| Intraoperative Complications | 2 | 1996 | 126 | 0.240 |
Why?
| Laparoscopy | 1 | 2008 | 400 | 0.240 |
Why?
| Adult | 22 | 2020 | 30820 | 0.230 |
Why?
| Attitude of Health Personnel | 1 | 2011 | 990 | 0.230 |
Why?
| Neurosurgeons | 1 | 2023 | 13 | 0.230 |
Why?
| Nuclear Proteins | 3 | 2017 | 594 | 0.220 |
Why?
| Autophagy | 2 | 2017 | 236 | 0.220 |
Why?
| Spinal Neoplasms | 1 | 2003 | 29 | 0.220 |
Why?
| Indoles | 2 | 2017 | 309 | 0.220 |
Why?
| Tumor Suppressor Proteins | 3 | 2017 | 286 | 0.220 |
Why?
| Patients' Rooms | 1 | 2022 | 13 | 0.210 |
Why?
| Cell Proliferation | 8 | 2019 | 2196 | 0.210 |
Why?
| Electroencephalography | 4 | 2018 | 366 | 0.210 |
Why?
| Osteosarcoma | 1 | 2003 | 66 | 0.210 |
Why?
| Narcotics | 1 | 2022 | 45 | 0.210 |
Why?
| Combined Modality Therapy | 7 | 2015 | 1128 | 0.210 |
Why?
| Cell Cycle Proteins | 3 | 2016 | 555 | 0.200 |
Why?
| Sulfonamides | 2 | 2017 | 447 | 0.200 |
Why?
| Histiocytosis, Langerhans-Cell | 1 | 2022 | 35 | 0.200 |
Why?
| Drug Screening Assays, Antitumor | 2 | 2021 | 180 | 0.200 |
Why?
| Antineoplastic Agents | 3 | 2018 | 1891 | 0.190 |
Why?
| Radiation | 1 | 2021 | 25 | 0.190 |
Why?
| SEER Program | 4 | 2018 | 193 | 0.190 |
Why?
| Chemoradiotherapy | 2 | 2019 | 187 | 0.190 |
Why?
| Lumbosacral Region | 1 | 2021 | 47 | 0.190 |
Why?
| Scoliosis | 2 | 2011 | 181 | 0.190 |
Why?
| Parietal Bone | 1 | 2000 | 12 | 0.190 |
Why?
| Transcription Factor RelA | 2 | 2019 | 83 | 0.190 |
Why?
| Connective Tissue | 1 | 2000 | 36 | 0.190 |
Why?
| Skull Fractures | 1 | 2000 | 28 | 0.190 |
Why?
| Epilepsies, Partial | 2 | 2018 | 31 | 0.180 |
Why?
| Inclusion Bodies | 2 | 2012 | 24 | 0.180 |
Why?
| Diagnosis, Computer-Assisted | 1 | 2020 | 64 | 0.180 |
Why?
| Neoplastic Cells, Circulating | 1 | 2020 | 59 | 0.170 |
Why?
| Biopsy | 3 | 2018 | 1056 | 0.170 |
Why?
| Data Collection | 2 | 2014 | 636 | 0.170 |
Why?
| Reverse Transcriptase Polymerase Chain Reaction | 6 | 2014 | 934 | 0.170 |
Why?
| Obstetric Surgical Procedures | 1 | 2019 | 5 | 0.170 |
Why?
| Prenatal Care | 2 | 2022 | 257 | 0.170 |
Why?
| Follow-Up Studies | 7 | 2018 | 4446 | 0.170 |
Why?
| Optic Nerve Neoplasms | 1 | 2019 | 12 | 0.170 |
Why?
| Positron-Emission Tomography | 2 | 2018 | 290 | 0.170 |
Why?
| Optic Chiasm | 1 | 2019 | 18 | 0.170 |
Why?
| Fetal Therapies | 1 | 2019 | 30 | 0.160 |
Why?
| Maternal Health | 1 | 2019 | 44 | 0.160 |
Why?
| Pteridines | 2 | 2016 | 21 | 0.160 |
Why?
| Single-Cell Analysis | 1 | 2020 | 181 | 0.160 |
Why?
| Neuroblastoma | 1 | 2019 | 130 | 0.160 |
Why?
| Astrocytes | 2 | 2012 | 165 | 0.160 |
Why?
| Microarray Analysis | 5 | 2017 | 120 | 0.160 |
Why?
| Hysterotomy | 1 | 2017 | 10 | 0.150 |
Why?
| Occipital Lobe | 1 | 2017 | 23 | 0.150 |
Why?
| Cyst Fluid | 1 | 2017 | 27 | 0.150 |
Why?
| Fetoscopy | 1 | 2017 | 28 | 0.150 |
Why?
| Disease Management | 1 | 2021 | 562 | 0.150 |
Why?
| Fluorodeoxyglucose F18 | 1 | 2018 | 126 | 0.150 |
Why?
| Drug Resistant Epilepsy | 1 | 2018 | 47 | 0.150 |
Why?
| Chordoma | 1 | 2017 | 13 | 0.150 |
Why?
| Neoadjuvant Therapy | 1 | 2019 | 301 | 0.150 |
Why?
| Skull Base Neoplasms | 1 | 2017 | 26 | 0.140 |
Why?
| Meningioma | 1 | 2018 | 77 | 0.140 |
Why?
| Tuberous Sclerosis | 1 | 2017 | 37 | 0.140 |
Why?
| Equipment Failure | 2 | 2013 | 109 | 0.140 |
Why?
| Meningeal Neoplasms | 1 | 2018 | 87 | 0.140 |
Why?
| Chromosome Aberrations | 1 | 2017 | 136 | 0.140 |
Why?
| Young Adult | 12 | 2021 | 10518 | 0.140 |
Why?
| Neuroimaging | 1 | 2019 | 251 | 0.140 |
Why?
| Drug Resistance, Neoplasm | 3 | 2017 | 638 | 0.140 |
Why?
| Neoplasm Proteins | 2 | 2012 | 388 | 0.140 |
Why?
| Checkpoint Kinase 1 | 1 | 2016 | 28 | 0.140 |
Why?
| Electrocoagulation | 1 | 1996 | 38 | 0.140 |
Why?
| Tissue Banks | 1 | 2016 | 18 | 0.140 |
Why?
| Frontal Lobe | 1 | 2017 | 140 | 0.140 |
Why?
| Electrodes, Implanted | 1 | 2017 | 93 | 0.140 |
Why?
| Radiation-Sensitizing Agents | 1 | 2016 | 38 | 0.140 |
Why?
| B7-H1 Antigen | 1 | 2018 | 138 | 0.140 |
Why?
| Onchocerca | 1 | 2015 | 2 | 0.130 |
Why?
| Myeloid Cells | 2 | 2015 | 127 | 0.130 |
Why?
| Decision Support Techniques | 1 | 2019 | 352 | 0.130 |
Why?
| Zoonoses | 1 | 2015 | 21 | 0.130 |
Why?
| Ketorolac | 1 | 2015 | 17 | 0.130 |
Why?
| Algorithms | 2 | 2020 | 1494 | 0.130 |
Why?
| Communicable Diseases, Emerging | 1 | 2015 | 28 | 0.130 |
Why?
| Risk Factors | 7 | 2019 | 8714 | 0.130 |
Why?
| EGF Family of Proteins | 1 | 2015 | 15 | 0.130 |
Why?
| Survivors | 2 | 2023 | 405 | 0.130 |
Why?
| Dog Diseases | 1 | 2015 | 41 | 0.130 |
Why?
| MicroRNAs | 2 | 2012 | 610 | 0.130 |
Why?
| Cohort Studies | 8 | 2021 | 4960 | 0.130 |
Why?
| Receptor, EphA2 | 1 | 2015 | 19 | 0.130 |
Why?
| Lymphocyte Specific Protein Tyrosine Kinase p56(lck) | 1 | 2015 | 21 | 0.130 |
Why?
| Temporal Lobe | 1 | 2015 | 83 | 0.130 |
Why?
| Receptor, ErbB-3 | 1 | 2015 | 42 | 0.130 |
Why?
| Spinal Cord Diseases | 1 | 2015 | 39 | 0.120 |
Why?
| Choroid Plexus Neoplasms | 1 | 2014 | 8 | 0.120 |
Why?
| Image Interpretation, Computer-Assisted | 1 | 2016 | 219 | 0.120 |
Why?
| Recurrence | 2 | 2016 | 949 | 0.120 |
Why?
| Lumbar Vertebrae | 1 | 2016 | 217 | 0.120 |
Why?
| Ventriculostomy | 1 | 1994 | 17 | 0.120 |
Why?
| src-Family Kinases | 1 | 2015 | 87 | 0.120 |
Why?
| Endoscopes | 1 | 1994 | 18 | 0.120 |
Why?
| Cytokines | 3 | 2017 | 1857 | 0.120 |
Why?
| Encephalitis | 1 | 2016 | 128 | 0.120 |
Why?
| Perioperative Care | 1 | 2015 | 127 | 0.120 |
Why?
| Neoplasm Staging | 3 | 2019 | 1177 | 0.120 |
Why?
| Radiation Tolerance | 2 | 2012 | 92 | 0.120 |
Why?
| Kaplan-Meier Estimate | 5 | 2016 | 819 | 0.120 |
Why?
| Accidents, Traffic | 2 | 2012 | 170 | 0.120 |
Why?
| Time Factors | 4 | 2019 | 6186 | 0.110 |
Why?
| NF-kappa B | 1 | 2017 | 639 | 0.110 |
Why?
| Professional Practice | 1 | 2014 | 62 | 0.110 |
Why?
| STAT3 Transcription Factor | 1 | 2015 | 174 | 0.110 |
Why?
| Pediatrics | 1 | 2021 | 986 | 0.110 |
Why?
| Blotting, Western | 3 | 2014 | 1153 | 0.110 |
Why?
| Brain | 2 | 2023 | 2382 | 0.110 |
Why?
| Foreign-Body Migration | 1 | 2013 | 39 | 0.110 |
Why?
| Catheters | 1 | 2013 | 64 | 0.110 |
Why?
| Central Nervous System Neoplasms | 1 | 2015 | 125 | 0.110 |
Why?
| Proto-Oncogene Proteins c-myc | 1 | 2014 | 115 | 0.110 |
Why?
| Kidney Neoplasms | 2 | 2017 | 325 | 0.110 |
Why?
| B7 Antigens | 1 | 2012 | 9 | 0.110 |
Why?
| Prevalence | 2 | 2016 | 2270 | 0.110 |
Why?
| Epigenesis, Genetic | 2 | 2017 | 531 | 0.110 |
Why?
| Survival Analysis | 3 | 2014 | 1221 | 0.110 |
Why?
| Neurology | 1 | 2014 | 85 | 0.110 |
Why?
| Spinal Dysraphism | 1 | 2013 | 43 | 0.110 |
Why?
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2015 | 301 | 0.110 |
Why?
| Fatty Liver, Alcoholic | 1 | 2012 | 16 | 0.110 |
Why?
| Neuroectodermal Tumors, Primitive | 1 | 2012 | 12 | 0.110 |
Why?
| Drug Delivery Systems | 1 | 2015 | 301 | 0.100 |
Why?
| Persistent Vegetative State | 1 | 2012 | 4 | 0.100 |
Why?
| Lipase | 1 | 2012 | 65 | 0.100 |
Why?
| Seizures | 1 | 2015 | 343 | 0.100 |
Why?
| Incidence | 3 | 2017 | 2333 | 0.100 |
Why?
| Cell Survival | 4 | 2017 | 1026 | 0.100 |
Why?
| Immunohistochemistry | 3 | 2013 | 1643 | 0.100 |
Why?
| Rubinstein-Taybi Syndrome | 1 | 2011 | 2 | 0.100 |
Why?
| ErbB Receptors | 1 | 2015 | 557 | 0.100 |
Why?
| Body Mass Index | 1 | 2019 | 1982 | 0.100 |
Why?
| Glasgow Coma Scale | 1 | 2012 | 144 | 0.100 |
Why?
| Interleukin-6 | 1 | 2015 | 679 | 0.100 |
Why?
| Disabled Children | 1 | 2012 | 71 | 0.090 |
Why?
| Neurologic Examination | 1 | 2011 | 117 | 0.090 |
Why?
| Cerebellum | 1 | 2012 | 200 | 0.090 |
Why?
| Bone Morphogenetic Proteins | 1 | 2011 | 133 | 0.090 |
Why?
| Radiosurgery | 1 | 2014 | 298 | 0.090 |
Why?
| Heart Arrest | 1 | 1994 | 289 | 0.090 |
Why?
| Neoplastic Stem Cells | 1 | 2014 | 330 | 0.090 |
Why?
| Sex Factors | 1 | 2016 | 1741 | 0.090 |
Why?
| DNA Methylation | 2 | 2021 | 498 | 0.090 |
Why?
| Fatty Liver | 1 | 2012 | 217 | 0.090 |
Why?
| Disease Models, Animal | 1 | 2019 | 3582 | 0.090 |
Why?
| Transcription Factors | 2 | 2017 | 1531 | 0.090 |
Why?
| Morbidity | 2 | 2018 | 280 | 0.090 |
Why?
| Anilides | 1 | 2010 | 67 | 0.090 |
Why?
| Societies, Medical | 1 | 2014 | 690 | 0.090 |
Why?
| Medical Futility | 1 | 2010 | 19 | 0.090 |
Why?
| Phenotype | 2 | 2015 | 2861 | 0.090 |
Why?
| T-Lymphocytes | 2 | 2018 | 1758 | 0.090 |
Why?
| Surgeons | 1 | 2014 | 240 | 0.090 |
Why?
| RNA-Binding Proteins | 1 | 2013 | 365 | 0.090 |
Why?
| Apoptosis | 5 | 2019 | 2377 | 0.090 |
Why?
| Patient Discharge | 1 | 2016 | 770 | 0.090 |
Why?
| Surveys and Questionnaires | 1 | 2021 | 4670 | 0.090 |
Why?
| Survival Rate | 4 | 2019 | 1653 | 0.090 |
Why?
| United States | 6 | 2019 | 12338 | 0.080 |
Why?
| Quality of Life | 2 | 2015 | 2392 | 0.080 |
Why?
| Electrolytes | 1 | 2009 | 55 | 0.080 |
Why?
| Pediatric Nursing | 1 | 2009 | 40 | 0.080 |
Why?
| Antibodies, Neoplasm | 1 | 2009 | 29 | 0.080 |
Why?
| Claudins | 1 | 2009 | 24 | 0.080 |
Why?
| Intracranial Arteriovenous Malformations | 1 | 2009 | 51 | 0.080 |
Why?
| Radiotherapy Dosage | 1 | 2009 | 246 | 0.080 |
Why?
| RNA, Neoplasm | 1 | 2009 | 80 | 0.080 |
Why?
| Obesity | 2 | 2019 | 2530 | 0.080 |
Why?
| Medical Records | 1 | 2009 | 157 | 0.080 |
Why?
| Contractile Proteins | 1 | 2008 | 16 | 0.080 |
Why?
| Sodium | 1 | 2009 | 182 | 0.080 |
Why?
| Apoptosis Regulatory Proteins | 1 | 2009 | 175 | 0.080 |
Why?
| Salvage Therapy | 1 | 2009 | 128 | 0.080 |
Why?
| Fluid Therapy | 1 | 2009 | 120 | 0.080 |
Why?
| Point Mutation | 1 | 2009 | 218 | 0.080 |
Why?
| Prospective Studies | 4 | 2019 | 6267 | 0.080 |
Why?
| Middle Aged | 9 | 2020 | 27084 | 0.080 |
Why?
| Polymorphism, Single Nucleotide | 2 | 2013 | 2020 | 0.080 |
Why?
| Microtubule-Associated Proteins | 1 | 2009 | 176 | 0.080 |
Why?
| Recovery of Function | 1 | 2012 | 578 | 0.080 |
Why?
| Neoplasm Grading | 2 | 2021 | 244 | 0.080 |
Why?
| Catheterization | 1 | 2008 | 160 | 0.080 |
Why?
| Real-Time Polymerase Chain Reaction | 3 | 2014 | 319 | 0.070 |
Why?
| Microfilament Proteins | 1 | 2008 | 127 | 0.070 |
Why?
| Consensus | 1 | 2010 | 533 | 0.070 |
Why?
| Vertebral Artery Dissection | 1 | 2007 | 18 | 0.070 |
Why?
| DNA Modification Methylases | 1 | 2007 | 14 | 0.070 |
Why?
| Pyrimidines | 1 | 2010 | 376 | 0.070 |
Why?
| Vertebral Artery | 1 | 2007 | 25 | 0.070 |
Why?
| Autopsy | 2 | 2012 | 86 | 0.070 |
Why?
| DNA Repair Enzymes | 1 | 2007 | 23 | 0.070 |
Why?
| Antineoplastic Agents, Alkylating | 1 | 2007 | 68 | 0.070 |
Why?
| Disease Progression | 3 | 2012 | 2424 | 0.070 |
Why?
| Dacarbazine | 1 | 2007 | 100 | 0.070 |
Why?
| Metabolic Clearance Rate | 1 | 2007 | 108 | 0.070 |
Why?
| Vascular Diseases | 1 | 2009 | 230 | 0.070 |
Why?
| Prostheses and Implants | 1 | 2007 | 141 | 0.070 |
Why?
| Colorado | 2 | 2019 | 4122 | 0.070 |
Why?
| Proteomics | 1 | 2012 | 855 | 0.070 |
Why?
| Infusions, Intravenous | 1 | 2007 | 374 | 0.070 |
Why?
| Computer Simulation | 2 | 2021 | 887 | 0.070 |
Why?
| Athletic Injuries | 1 | 2012 | 455 | 0.060 |
Why?
| Nerve Tissue Proteins | 1 | 2009 | 538 | 0.060 |
Why?
| Cell Cycle | 3 | 2014 | 546 | 0.060 |
Why?
| Tumor Cells, Cultured | 2 | 2019 | 850 | 0.060 |
Why?
| Tumor Microenvironment | 2 | 2022 | 424 | 0.060 |
Why?
| Embolization, Therapeutic | 1 | 2007 | 181 | 0.060 |
Why?
| Pregnancy | 4 | 2022 | 5556 | 0.060 |
Why?
| Signal Transduction | 2 | 2015 | 4526 | 0.060 |
Why?
| Drug Synergism | 2 | 2017 | 316 | 0.060 |
Why?
| Age Factors | 3 | 2019 | 2912 | 0.060 |
Why?
| Xenograft Model Antitumor Assays | 2 | 2019 | 703 | 0.060 |
Why?
| Gene Expression | 4 | 2015 | 1442 | 0.060 |
Why?
| Thoracic Vertebrae | 2 | 2003 | 71 | 0.060 |
Why?
| Disease-Free Survival | 2 | 2016 | 621 | 0.060 |
Why?
| Endothelial Cells | 1 | 2009 | 694 | 0.060 |
Why?
| X-ray Repair Cross Complementing Protein 1 | 1 | 2023 | 14 | 0.060 |
Why?
| Intelligence Tests | 1 | 2023 | 59 | 0.060 |
Why?
| Bleomycin | 2 | 2009 | 232 | 0.060 |
Why?
| Palliative Care | 1 | 2010 | 643 | 0.060 |
Why?
| Twins, Conjoined | 1 | 2003 | 4 | 0.060 |
Why?
| Stereotaxic Techniques | 1 | 2003 | 28 | 0.060 |
Why?
| Survival | 1 | 2003 | 37 | 0.060 |
Why?
| Cranial Irradiation | 1 | 2023 | 66 | 0.060 |
Why?
| Diagnosis, Differential | 2 | 2012 | 1359 | 0.050 |
Why?
| Up-Regulation | 2 | 2016 | 824 | 0.050 |
Why?
| Mice | 5 | 2022 | 15075 | 0.050 |
Why?
| Multivariate Analysis | 2 | 2017 | 1444 | 0.050 |
Why?
| Conservative Treatment | 1 | 2022 | 29 | 0.050 |
Why?
| Animals | 7 | 2022 | 32123 | 0.050 |
Why?
| Gene Ontology | 1 | 2021 | 45 | 0.050 |
Why?
| Vitamin K Deficiency | 1 | 2000 | 10 | 0.050 |
Why?
| Disseminated Intravascular Coagulation | 1 | 2000 | 30 | 0.050 |
Why?
| Databases, Factual | 2 | 2016 | 1149 | 0.050 |
Why?
| Hedgehog Proteins | 1 | 2022 | 172 | 0.050 |
Why?
| DNA Copy Number Variations | 1 | 2021 | 157 | 0.050 |
Why?
| Proportional Hazards Models | 2 | 2015 | 1088 | 0.050 |
Why?
| Lymphocytes, Tumor-Infiltrating | 2 | 2012 | 107 | 0.050 |
Why?
| Cluster Analysis | 2 | 2013 | 466 | 0.040 |
Why?
| Preoperative Period | 1 | 2020 | 103 | 0.040 |
Why?
| Risk Assessment | 2 | 2019 | 3004 | 0.040 |
Why?
| Herpes Simplex | 1 | 2000 | 88 | 0.040 |
Why?
| Fatal Outcome | 1 | 2000 | 286 | 0.040 |
Why?
| Cross-Sectional Studies | 1 | 2010 | 4449 | 0.040 |
Why?
| Diseases in Twins | 1 | 2000 | 175 | 0.040 |
Why?
| Aged, 80 and over | 3 | 2018 | 6438 | 0.040 |
Why?
| Spinal Fusion | 1 | 2002 | 217 | 0.040 |
Why?
| Neuropsychological Tests | 1 | 2023 | 932 | 0.040 |
Why?
| Perinatal Death | 1 | 2019 | 22 | 0.040 |
Why?
| Antibiotics, Antineoplastic | 1 | 1999 | 114 | 0.040 |
Why?
| Mice, SCID | 1 | 2019 | 321 | 0.040 |
Why?
| DNA, Antisense | 1 | 1998 | 3 | 0.040 |
Why?
| Cysts | 1 | 1999 | 94 | 0.040 |
Why?
| Cytoreduction Surgical Procedures | 1 | 2019 | 40 | 0.040 |
Why?
| Heparan Sulfate Proteoglycans | 1 | 1998 | 22 | 0.040 |
Why?
| Stroke | 1 | 2007 | 1014 | 0.040 |
Why?
| Radiotherapy, Conformal | 1 | 2019 | 68 | 0.040 |
Why?
| Heparitin Sulfate | 1 | 1998 | 42 | 0.040 |
Why?
| Hemispherectomy | 1 | 2018 | 3 | 0.040 |
Why?
| Mutation | 3 | 2014 | 3371 | 0.040 |
Why?
| Brain Diseases | 1 | 1999 | 127 | 0.040 |
Why?
| Fetus | 1 | 2022 | 703 | 0.040 |
Why?
| Proteoglycans | 1 | 1998 | 108 | 0.040 |
Why?
| Radiography | 1 | 2000 | 826 | 0.040 |
Why?
| Mice, Inbred NOD | 1 | 2019 | 562 | 0.040 |
Why?
| Vincristine | 1 | 1998 | 96 | 0.040 |
Why?
| Drug Approval | 1 | 2018 | 78 | 0.040 |
Why?
| Carboplatin | 1 | 1998 | 139 | 0.040 |
Why?
| Neoplasms, Experimental | 1 | 1998 | 153 | 0.040 |
Why?
| Receptors, HIV | 1 | 2017 | 23 | 0.040 |
Why?
| Mucin-1 | 1 | 2017 | 18 | 0.040 |
Why?
| Receptors, Interleukin-6 | 1 | 2017 | 35 | 0.040 |
Why?
| Cytogenetic Analysis | 1 | 2017 | 29 | 0.040 |
Why?
| Indoleamine-Pyrrole 2,3,-Dioxygenase | 1 | 2017 | 44 | 0.040 |
Why?
| Rhabdomyoma | 1 | 2017 | 10 | 0.040 |
Why?
| Angiomyolipoma | 1 | 2017 | 18 | 0.040 |
Why?
| Fibroblast Growth Factors | 1 | 1998 | 162 | 0.040 |
Why?
| Drug Administration Schedule | 1 | 2019 | 724 | 0.040 |
Why?
| Headache | 1 | 1998 | 131 | 0.040 |
Why?
| Glial Fibrillary Acidic Protein | 1 | 2017 | 82 | 0.040 |
Why?
| Ki-67 Antigen | 1 | 2017 | 104 | 0.040 |
Why?
| Carcinoma | 2 | 2014 | 200 | 0.040 |
Why?
| Antineoplastic Agents, Phytogenic | 1 | 1998 | 181 | 0.040 |
Why?
| Heart Neoplasms | 1 | 2017 | 50 | 0.040 |
Why?
| Neovascularization, Pathologic | 1 | 1998 | 283 | 0.040 |
Why?
| Clinical Decision-Making | 1 | 2019 | 275 | 0.040 |
Why?
| Benzodiazepinones | 1 | 2016 | 14 | 0.040 |
Why?
| Tertiary Care Centers | 1 | 2017 | 127 | 0.030 |
Why?
| Models, Theoretical | 1 | 2020 | 527 | 0.030 |
Why?
| Organ Size | 1 | 2017 | 435 | 0.030 |
Why?
| Genes, myc | 1 | 2016 | 47 | 0.030 |
Why?
| Computational Biology | 1 | 2020 | 528 | 0.030 |
Why?
| Gestational Age | 1 | 2019 | 757 | 0.030 |
Why?
| Urea | 1 | 2016 | 69 | 0.030 |
Why?
| Microscopy, Confocal | 1 | 2017 | 298 | 0.030 |
Why?
| Thiophenes | 1 | 2016 | 107 | 0.030 |
Why?
| Southwestern United States | 1 | 2015 | 92 | 0.030 |
Why?
| Genotype | 2 | 2012 | 1842 | 0.030 |
Why?
| Transcriptional Activation | 1 | 2017 | 341 | 0.030 |
Why?
| Feasibility Studies | 1 | 2018 | 750 | 0.030 |
Why?
| Amphiregulin | 1 | 2015 | 21 | 0.030 |
Why?
| Cats | 1 | 2015 | 205 | 0.030 |
Why?
| Neoplasm Metastasis | 1 | 2017 | 526 | 0.030 |
Why?
| Specimen Handling | 1 | 2016 | 157 | 0.030 |
Why?
| Molecular Targeted Therapy | 1 | 2018 | 348 | 0.030 |
Why?
| Cisplatin | 1 | 2016 | 263 | 0.030 |
Why?
| Lipopolysaccharide Receptors | 1 | 2015 | 85 | 0.030 |
Why?
| Dogs | 1 | 2015 | 344 | 0.030 |
Why?
| DNA Damage | 1 | 2016 | 356 | 0.030 |
Why?
| Health Status | 1 | 2019 | 733 | 0.030 |
Why?
| Azepines | 1 | 2014 | 73 | 0.030 |
Why?
| Imaging, Three-Dimensional | 1 | 2017 | 496 | 0.030 |
Why?
| Cost of Illness | 1 | 2015 | 258 | 0.030 |
Why?
| Sequence Analysis, DNA | 1 | 2016 | 733 | 0.030 |
Why?
| Receptors, IgG | 1 | 2013 | 66 | 0.030 |
Why?
| Pyrazoles | 1 | 2016 | 362 | 0.030 |
Why?
| Promoter Regions, Genetic | 1 | 2017 | 1129 | 0.030 |
Why?
| Cathepsin B | 1 | 2012 | 14 | 0.030 |
Why?
| Monitoring, Physiologic | 1 | 2015 | 252 | 0.030 |
Why?
| Triazoles | 1 | 2014 | 131 | 0.030 |
Why?
| Rapamycin-Insensitive Companion of mTOR Protein | 1 | 2012 | 28 | 0.030 |
Why?
| Argonaute Proteins | 1 | 2012 | 28 | 0.030 |
Why?
| Exons | 1 | 2013 | 303 | 0.030 |
Why?
| Kansas | 1 | 2012 | 29 | 0.030 |
Why?
| Missouri | 1 | 2012 | 63 | 0.030 |
Why?
| Cyclin-Dependent Kinase 6 | 1 | 2012 | 37 | 0.030 |
Why?
| Karnofsky Performance Status | 1 | 2012 | 36 | 0.030 |
Why?
| Aged | 3 | 2018 | 19299 | 0.030 |
Why?
| HLA-DR Antigens | 1 | 2013 | 220 | 0.030 |
Why?
| Mice, Nude | 1 | 2014 | 639 | 0.030 |
Why?
| Logistic Models | 1 | 2017 | 1865 | 0.030 |
Why?
| Monocytes | 1 | 2015 | 504 | 0.030 |
Why?
| Hyalin | 1 | 2012 | 5 | 0.030 |
Why?
| 3' Untranslated Regions | 1 | 2012 | 137 | 0.030 |
Why?
| Inflammation Mediators | 1 | 2015 | 481 | 0.030 |
Why?
| Carbonic Anhydrases | 1 | 2012 | 14 | 0.030 |
Why?
| Resuscitation | 1 | 1994 | 248 | 0.030 |
Why?
| Catalase | 1 | 2012 | 118 | 0.020 |
Why?
| CREB-Binding Protein | 1 | 2011 | 26 | 0.020 |
Why?
| Neural Stem Cells | 1 | 2012 | 114 | 0.020 |
Why?
| Neoplasm Invasiveness | 1 | 2012 | 445 | 0.020 |
Why?
| In Situ Hybridization, Fluorescence | 1 | 2012 | 310 | 0.020 |
Why?
| Phosphorylation | 1 | 2015 | 1561 | 0.020 |
Why?
| Gastrostomy | 1 | 2011 | 89 | 0.020 |
Why?
| Liver Cirrhosis | 1 | 2012 | 240 | 0.020 |
Why?
| Aurora Kinases | 1 | 2010 | 28 | 0.020 |
Why?
| Twins, Monozygotic | 1 | 2011 | 211 | 0.020 |
Why?
| DNA-Binding Proteins | 1 | 2017 | 1319 | 0.020 |
Why?
| Aurora Kinase A | 1 | 2010 | 51 | 0.020 |
Why?
| Physical Examination | 1 | 2011 | 224 | 0.020 |
Why?
| Skin Neoplasms | 1 | 2017 | 760 | 0.020 |
Why?
| Antidiuretic Agents | 1 | 2009 | 7 | 0.020 |
Why?
| Hypernatremia | 1 | 2009 | 7 | 0.020 |
Why?
| Deamino Arginine Vasopressin | 1 | 2009 | 10 | 0.020 |
Why?
| KRIT1 Protein | 1 | 2009 | 6 | 0.020 |
Why?
| Repressor Proteins | 1 | 2012 | 369 | 0.020 |
Why?
| High-Throughput Nucleotide Sequencing | 1 | 2012 | 446 | 0.020 |
Why?
| Hyponatremia | 1 | 2009 | 37 | 0.020 |
Why?
| Non-alcoholic Fatty Liver Disease | 1 | 2012 | 246 | 0.020 |
Why?
| Electronic Health Records | 1 | 2016 | 801 | 0.020 |
Why?
| Carrier Proteins | 1 | 2012 | 703 | 0.020 |
Why?
| Enzyme Inhibitors | 1 | 2012 | 758 | 0.020 |
Why?
| Filamins | 1 | 2008 | 19 | 0.020 |
Why?
| Cell Movement | 1 | 2012 | 868 | 0.020 |
Why?
| Cell Division | 1 | 2010 | 760 | 0.020 |
Why?
| DNA Mutational Analysis | 1 | 2009 | 378 | 0.020 |
Why?
| Fibrous Dysplasia, Monostotic | 1 | 1987 | 1 | 0.020 |
Why?
| Microscopy, Electron, Transmission | 1 | 2008 | 138 | 0.020 |
Why?
| Fibrous Dysplasia of Bone | 1 | 1987 | 5 | 0.020 |
Why?
| Radiotherapy | 1 | 2009 | 177 | 0.020 |
Why?
| Gene Frequency | 1 | 2009 | 507 | 0.020 |
Why?
| Spinal Diseases | 1 | 1987 | 45 | 0.020 |
Why?
| Cerebral Angiography | 1 | 2007 | 111 | 0.020 |
Why?
| Etoposide | 1 | 2007 | 149 | 0.020 |
Why?
| DNA, Neoplasm | 1 | 2007 | 156 | 0.020 |
Why?
| Gene Silencing | 1 | 2007 | 176 | 0.020 |
Why?
| Dose-Response Relationship, Drug | 1 | 2010 | 1868 | 0.020 |
Why?
| RNA | 1 | 2012 | 821 | 0.020 |
Why?
| Magnetic Resonance Angiography | 1 | 2007 | 209 | 0.020 |
Why?
| Lung Neoplasms | 1 | 2017 | 2207 | 0.010 |
Why?
| Anticoagulants | 1 | 2007 | 545 | 0.010 |
Why?
| Instillation, Drug | 1 | 1999 | 9 | 0.010 |
Why?
| Injections, Intralesional | 1 | 1999 | 32 | 0.010 |
Why?
| Fibroblast Growth Factor 7 | 1 | 1998 | 16 | 0.010 |
Why?
| Fibroblast Growth Factor 10 | 1 | 1998 | 24 | 0.010 |
Why?
| Growth Substances | 1 | 1998 | 136 | 0.010 |
Why?
| Fibroblast Growth Factor 2 | 1 | 1998 | 83 | 0.010 |
Why?
| Neoplasm Transplantation | 1 | 1998 | 235 | 0.010 |
Why?
| Aging | 1 | 1988 | 1640 | 0.010 |
Why?
| Melanoma, Experimental | 1 | 1998 | 118 | 0.010 |
Why?
| Colonic Neoplasms | 1 | 1998 | 221 | 0.010 |
Why?
| Protein Binding | 1 | 1998 | 1919 | 0.010 |
Why?
| Body Height | 1 | 1988 | 185 | 0.000 |
Why?
|
|
Handler's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|